Saturday 17 October 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024. In the quarter to June 2026, revenue grew 55.4%, EPS grew 37.5% and free cash flow grew 66.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for five.

78.59 1.35 −1.69%

Follow KNSA

Alert me

Market cap: $6.2B
P/E: 73.4×
Fwd P/E: 38.7×
Dividend yield: —
F-score: 8/9
Altman Z: 10.35
Beneish M: −3.16
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 42.71

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	3	1	3	1	7	2	—	1	—	—	—

Insider Ownership 41.97%

Capital & Financial Ratios $m

Market Cap 6,240.00

Revenue 840.85

Net Income 80.66

Free Cash Flow 182.84

Net Debt (525.93)

Current Ratio 3.90

Debt/Equity 0.00

P/E ratio 73.45

Fwd P/E 38.70

P/S ratio 7.25

P/B ratio 9.32

Past 5Y EPS Growth —

This Y EPS Growth 82.04%

Next Y EPS Growth 48.14%

Next Y revenue growth 46.76%

Next 5Y EPS Growth 53.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 87.20%

10-year low 10-year high

P/B against its own 10 years 99.04%

10-year low 10-year high

EV/Sales against its own 10 years 90.80%

10-year low 10-year high

EV/FCF against its own 10 years 50.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	206	244	414	526
Receivables	21	42	16	23
Inventory	31	26	55	71
Other	—	—	—	—
	276	332	527	669

	2023	2024	2025	Q'26
Payables	8	2	2	12
ST’ Debt	—	—	—	—
Other	8	16	22	20
	64	101	139	171

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	45.45%
Cash Flow	—	0.00%	187.49%
Earnings	—	0.00%	(31.47%)
Book Value	—	12.72%	12.74%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	214	244	—	—	—
’25	138	157	181	202	678
’24	80	109	112	123	423
’23	48	71	67	83	270
’22	32	27	99	62	220

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	50	47	—	—	—
’25	22	28	34	54	138
’24	4	5	(2)	19	26
’23	(4)	(4)	17	4	13
’22	(37)	(8)	62	(12)	6
’21	(40)	(39)	(29)	(19)	(126)
’20	(32)	(29)	(34)	(41)	(137)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	50	47	—	—	—
’25	22	28	33	53	136
’24	4	5	(2)	19	25
’23	(4)	(4)	17	4	13
’22	(37)	(8)	62	(12)	6
’21	(60)	(39)	(29)	(19)	(147)
’20	(32)	(29)	(34)	(41)	(137)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.27	0.30	—	—	—
’25	0.11	0.23	0.23	0.17	0.75
’24	(0.25)	(0.06)	(0.18)	(0.12)	(0.60)
’23	(0.18)	0.21	(0.20)	0.35	0.20
’22	(0.36)	(0.29)	3.18	0.06	2.60
’21	(0.72)	(0.61)	(0.44)	(0.53)	(2.30)
’20	(0.48)	(0.65)	(0.66)	(0.79)	(2.61)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	13.04	5.01	10.30	10.30	7.36	10.29	16.56	17.82	Analyst estimates 2026–2028 Powerpack
	High	—	—	32.88	28.43	28.67	24.70	17.20	20.65	28.15	44.42
People
People	Employees	—	47	111	137	168	215	220	297	315	366
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.18	1.00	0.91	1.34	1.85
Income, $m
Income, $m	Revenue	—	—	—	—	—	39	220	270	423	678
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	76.39	89.60	87.64	85.61	88.54
	EBT	(24)	(65)	(103)	(164)	(156)	(157)	11	(17)	(36)	89
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(406.13)	5.01	(6.16)	(8.54)	13.12
	Net income	(24)	(65)	(103)	(162)	(161)	(158)	183	14	(43)	59
	Depreciation	0	0	0	2	2	2	2	2	2	2
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.56	3.17	3.86	5.93	9.13
	Earnings	(91.61)	(35.84)	(3.49)	(2.99)	(2.61)	(2.30)	2.64	0.20	(0.60)	0.80
	Cash flow	(83.56)	(27.75)	(2.74)	(2.93)	(2.21)	(1.84)	0.08	0.19	0.36	1.86
	Capex	(0.01)	(0.04)	(0.18)	(0.06)	0.00	(0.30)	0.00	0.00	0.00	(0.02)
	Free cash flow	(83.57)	(27.78)	(2.92)	(2.99)	(2.21)	(2.14)	0.08	0.19	0.36	1.84
	Book value	206.97	16.61	9.45	4.17	5.04	2.70	5.71	6.26	6.14	7.65
	Shares, m	0	2	30	54	62	69	69	70	71	74
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	5.47	97.53	0.00	51.56
	P/S	—	—	—	—	—	0.00	4.55	4.80	3.34	4.52
	P/B	—	—	—	—	—	4.36	2.53	2.96	3.22	5.39
	EV/Sales	—	—	—	—	—	0.00	3.68	4.04	2.76	3.91
	EV/FCF	—	—	—	—	—	(4.26)	144.02	82.33	45.80	19.39
Cash, $m
Cash, $m	Operating cash flow	(22)	(50)	(81)	(158)	(137)	(126)	6	13	26	138
	Capex	0	0	(5)	(3)	0	(20)	0	0	0	(2)
	Free cash flow	(22)	(50)	(86)	(162)	(137)	(147)	6	13	25	136
Balance, $m
Balance, $m	Working capital	54	30	271	214	301	152	196	213	231	388
	Total debt	—	—	—	3	7	6	6	—	—	—
	Net debt	(56)	(46)	(307)	(233)	(324)	(182)	(191)	(206)	(244)	(414)
	Shareholders’ equity	54	30	279	225	312	185	396	439	438	568
Returns, %
Returns, %	ROA	(46.12)	(124.80)	(55.88)	(56.16)	(53.44)	(54.24)	52.96	2.86	(7.80)	8.78
	ROIC	0.00	0.00	0.00	0.00	0.00	(3,451.96)	2.97	(6.77)	(14.63)	31.44
	ROE	41.53	112.39	(108.91)	(64.15)	(60.06)	(63.55)	63.10	3.37	(9.85)	11.73

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
HIMS Hims & Hers Health, Inc.	$6.9B	— (loss-making)	— (loss-making)	+38.25% (above 0%: growing)	n/m	+5.09% (above 0%: growing)	63.83%	(12.90%)	Compare
ALKS Alkermes plc	$6.7B	102×	— (loss-making)	+26.97% (above 0%: growing)	−99.43% (below 0%: shrinking)	+1.13% (above 0%: growing)	80.22%	3.70%	Compare
LNTH Lantheus Holdings, Inc.	$6.5B	23.7×	25.3×	+2.68% (above 0%: growing)	0.00%	+13.55% (above 0%: growing)	62.30%	25.82%	Compare
KNSA Kiniksa Pharmaceuticals International, plc	$6.2B	73.4×	38.7×	+55.36% (above 0%: growing)	+37.50% (above 0%: growing)	+66.63% (above 0%: growing)	90.32%	11.16%
AMRX AMNEAL PHARMACEUTICALS, INC.	$6.2B	38.4×	51.6×	+9.89% (above 0%: growing)	+157.14% (above 0%: growing)	−351.41% (below 0%: shrinking)	42.01%	16.30%	Compare
RGC Regencell Bioscience Holdings Limited	$4.7B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—	Compare
INDV Indivior Pharmaceuticals Inc.	$4.0B	11.2×	11.8×	+13.58% (above 0%: growing)	+580.00% (above 0%: growing)	+58.57% (above 0%: growing)	85.42%	46.36%	Compare
AMLX Amylyx Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	−100.61% (below 0%: shrinking)	n/m	−24.50% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$6.3B	32.9×	24.8×	+9.89%	0.00%	+3.11%	63.06%	4.81%

All 86 Drug Manufacturers Specialty & Generic stocks →

Kiniksa Pharmaceuticals International, plc (KNSA) key facts

Strength: Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
Kiniksa Pharmaceuticals International, plc (KNSA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
Net income was $59.0 million, or $0.80 per share (basic), a net margin of 8.71%.
As of October 16, 2026, KNSA traded at $78.59, a market capitalization of $6.2 billion.
At that price the stock trades at 73.4× trailing-twelve-month earnings and 7.3× sales.
Return on equity was 11.7% and debt-to-equity 0.00.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 10.35 (safe zone) for fiscal 2025.